definiens: shall havc the : mearung assigned in Section 5.4 . [ 1.31 means approved labelling for the First lntegrelin Product as set fonh on Appendix A. ] 1.32 means the amount billed by a Pany or an Affillale for sales of Co­Developed Products to an unrela ~ d Thirtl Party less : ( i ) discounts, including cash discounts ( including quantity discounts ) . charge·back payments and rebates granted to managed health care organizations or to federal . stale and local governments, their agencies, and purchasers and rcimbursers or to trade customers . Iincluding bul not hmlted 10, . wbolcSol1c : rs and chain and pharmacy buying groups ( wnh any such dISCOUnts or reductIOns whICh ate based on SoIles to the cuslomer of mulliple produCt~ belng allocated 10 the Co - Developed Product on the basis of iI methodology approved by the lSC ) . ( ii ) creditS or allowances actually granted upon claims, damaged goods . rejections or retums of Co - Dcveloped Products, including recalls, regardless of the Pany requesting such . ( iIi ) freight . postage . dllpping and iIl'Iurancc ch.ilrges actually allowed or paid for dclivery of Co - Dc : veloped Product, 10 the extent billed . ~iv ) commis.sions paid to Third Panlet ] and ( v ) lues . dUlles or odIcr govenunental ch.ilrges leVIed on . absorbed or otherwise imposed on sale of Co·Dc : veloped Products . Including wi!hoot limitation value­added taxes . or ( ) ! her governmental charges otherwIse measured by lhe billing amount, when Included m billmg, as adjUSted ror rebatC5 and refunds 1.33 means ( i ) unexpired IClleD patent ( includmg inventor 's cc : nirlCiites ) which have not been held mvalld or unenforceable by a coun of compelent jurisdiction from which no appeal c .. n be taken or has been taken wlthm the required time period . includmg 6 CONFIDENTIAL TREATMENT REOUESTE D